Krajina: Európska únia
Jazyk: angličtina
Zdroj: EMA (European Medicines Agency)
vestronidase alfa
Ultragenyx Germany GmbH
A16AB18
vestronidase alfa
Enzymes
Mucopolysaccharidosis VII
Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).
Revision: 7
Authorised
2018-08-23
21 B. PACKAGE LEAFLET 22 PACKAGE LEAFLET: INFORMATION FOR THE USER MEPSEVII 2 MG/ML CONCENTRATE FOR SOLUTION FOR INFUSION vestronidase alfa This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet (see section 4). WHAT IS IN THIS LEAFLET 1. What Mepsevii is and what it is used for 2. What you need to know before you are given Mepsevii 3. How Mepsevii is given 4. Possible side effects 5. How to store Mepsevii 6. Contents of the pack and other information 1. WHAT MEPSEVII IS AND WHAT IT IS USED FOR WHAT MEPSEVII IS Mepsevii contains an enzyme called vestronidase alfa. This belongs to a group of medicines called enzyme replacement therapies. It is used in adults and children of all ages with MPS VII to treat non- neurological manifestations of the disease (mucopolysaccharidosis VII, also known as Sly Syndrome). WHAT IS MPS VII MPS VII is an illness that runs in families, where the body does not produce enough of an enzyme called beta–glucuronidase. - This enzyme helps to break down sugars in the body called mucopolysaccharides. - Mucopolysaccharides are made in the body and they help build bones, cartilage, skin, and tendons. - These sugars are re-cycled all the time – new ones are made and old ones are broken down. - Without enough beta–glucuronidase, parts of these sugars build up in cells, leading to damage in the body. HOW MEPSEVII WORKS This medici Prečítajte si celý dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Mepsevii 2 mg/mL concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of concentrate contains 2 mg vestronidase alfa*. Each vial of 5 mL concentrate contains 10 mg vestronidase alfa. *Vestronidase alfa is a recombinant form of human beta-glucuronidase (rhGUS) and is produced in Chinese Hamster Ovary cell culture by recombinant DNA technology. Excipient(s) with known effect Each vial contains 17.8 _ _ mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). Colourless to slightly yellow solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be supervised by a healthcare professional experienced in the management of patients with MPS VII or other inherited metabolic disorders. Administration of vestronidase alfa should be carried out by an appropriately trained healthcare professional with the ability to manage medical emergencies. Posology The recommended dose of vestronidase alfa is 4 mg/kg of body weight administered by intravenous infusion every two weeks. To minimise the risk of hypersensitivity reactions, a non-sedating antihistamine with or without an antipyretic medicinal product should be administered 30-60 minutes prior to the start of the infusion (see section 4.4). Infusion should be avoided if the patient has an acute febrile or respiratory illness at the time. _Special populations _ _ _ _Elderly _ 3 The safety and efficacy of vestronidase alfa in patients ol Prečítajte si celý dokument